Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
This no news ****e is deathly. Would love to know what is going on
Hmmm, just counter thoughts imo this is not going to play out as before because the co is not in the same position. Also have to say I do not buy (or like for that matter) the repeated attacks on the CEO. He has said their aim is long term shareholder value, and no, they do not tweet much but they do progress the products. And that requires stages from development to commercialisation.
Multiple products progressed & now with distributors / in PHE award / otherwise positioned (i.e afaics UNICEF, US DoD) since last year, and that is his and the co's doing. For sure medical business tends to be slow, but if you take care to look there is steady progress to what is now the stage (i.e. getting products placed for sales) I wanted to see.
One final step, for the distributors and arrangements to deliver - it looks like we may have HCV and military sales, AIHL has also completed all prior steps (CE mark, trials with NHS, inclusion in PHE framework) and due release with Inspiration Healthcare, and BC should be well into their sales cycles for the Covid 96 kit - a lot of griping about the latter but it was CLEARLY stated in the presentation in the spring that sales cycles needed to be gone through and that it was early stage back then.
Anyway, nothing wrong with trading it but for me at least I'm not prepared to be out at this stage. ymmv ofc
LTH here - ironically considering Budd’s non- commercial approach, the best way to have managed a GDR investment over last 18mths has been to trade it based on hype rather than delivery of anything meaningful as they haven’t (delivered anything meaningful).
Going fwd I will be doing this and at c.50p I anticipate it will get hyped to various highs over next 6mths (notwithstanding the inevitable placement coming soon).
Do not however invest in GDR as a long term investment until Budd is removed.
"Scheduled Orders" link in the Resources and tools section of the Genedrive product pages. I haven't seen this before - Sadly it requires a login to access, thought for a moment Beckman were throwing us a branch. Seems Beckman have made quite a few recent updates to the site, the site is looking better and better.
https://www.beckman.com/reagents/genomic/viral-detection/genedrive-96-sars-cov-2/c73254
Looking through Danaher's aquisitions and considering their interest in Point of Care it seems highly likely they will aquire us at some point imo, I'm just not sure when.
Have been reading through some of Danaher's latest financial updates. Revenue for their Life Sciences business (including Beckman Coulter Life Sciences and Cytiva) is up 41.5% for Q2 2021. Life Sciences seems to be their biggest and fastest growing business bringing in over $10billion last year. They defintely know what they're doing! :)
http://filecache.investorroom.com/mr5ir_danaher/686/Q2%202021%20Danaher%20Earnings%20Presentation.pdf
I was hoping to find specific details and figures, about Beckman and Cytiva's revenue streams but no such luck yet. It's impressive and reassuring though to see how brilliant they are at what they do. Initially, after the Beckman/Genedrive shipment in March I had naively expected sales in the coming weeks, but the reality is the sales cycle takes much longer and is a series of well rehearsed steps that end with a closed deal. Beckman are experts at this, I think somebody posted before that they have a 6 month sales cycle. From my understanding the length varies depending on the size of the deals, so the larger the deal the longer a sales cycle will be. The minimum sales cycle (small deals) is around 3 months. We know Beckman and Danaher don't mess about, they do things big... and they're very good at it!
General information...
"The sales cycle is intended to comprise the workings of creating and closing a deal. This cycle could include as many steps as the organisation has found to be correct for their industry and their individual strategies"
"Ultimately, the size of a B2B sales cycle often varies depending on the item being sold. For smaller deals, a B2B sales cycle often falls around 3 months."
"For larger and more substantial sales, a B2B sales cycle is more likely to fall between 6 to 9 months."
I keep seeing the figure of '18mths' being 'no sales' quoted but I'm a little confused. If we're talking about our SARs product, it wasn't CE marked 'til end of May last year, which is surely just over 14 mths.
I agree the sales of the lab product have to date been dreadfully underwhelming but let's not drub the company with over exaggerations.
However, on a another point, this week it's exactly a year since the collaboration with Beckman Coulter was announced by RNS.
May be the BOD are waiting to mark the occasion with a nice juicy trading announcement.
One can dream....lol!
Leaving Budd's failures and missed deadlines. Everyone knows how quickly this can move up, we have seen it on Indian import license update until DB put speeding ticket out. Just imagine the sp reaction when material sales and revenue start kicking in, we will see many multiples of current SP.
Because of our current cash position and lack of sales many are watching from side lines. There is possibility of little bit more down side if sales are delayed further. But I strongly believe we can easily get over this and over long term the company will be profitable.
This presents a great opportunity at current levels, BUY or HOLD.
Jimi I agree Sales are going to pop up slowly but Budd let all the investors down by not making any sales in last 18 months.
The company has good products and great prospects but with Budd’s attitude we are are going to go anywhere.
He needs to go and I would certainly vote him down in next AGM
CTW if they EU deal fell through, there is no need to RNS it. Technically the market should get informed in any subsequent trading updates, but even the latest one seems to have gone missing. In the March trading update they suggested it was still ongoing, but just seems like a dangled carrot to most people now.
Jimi- you say it in your post, significant sales which is exactly what we have faiked to achirve during three eaves og a global pandemic. Budd had been hiding behind approvals, but now we have approvals for mulyiple target markrys he has still failed to sell any. Next he'll tell us they only want to focus on the USA as the prize is bigger, but are being held back due to lack of FDA approval. Very unlikely we will see anything from this EU deal, it does not take a whole year to close a small £10m order.
We’ve had an order from Beckman, we’ve had orders resume recently for the HCV assays. All in less than 6 months. Beckman’s sales cycle should be converting leads around now (based on at least 4 months typical sales marketing cycle). Aswell as that we’re expecting huge interest in Covid POC test and hearing loss tests both launching soon. Just a little bit more patience needed for what should be a massive re-rate IMO. There will be mini spikes in the meantime for news on the stepping stones, WHO, EUA etc etc.
Not being funny it does not take this long to do a deal!
Last info from the company was that the EU prospect was still live. If that had changed they would have been required to RNS it as a material change.
Things is we have no orders in 18 months…. We had a eu deal? Obviously fell through.
No not at all, we’ve had a few tasty, very promising early samples of the jam but not the finished product so to speak. It’s been anticipation and excitement of what’s to come that’s taken the price up to the £1-3 levels. Significant sales, contracts and orders will take the price even higher, and bring more stability. We’re very much still in the jam tomorrow phase! IMO :)
Jimi- isn't that preciseky what has happened here? The shares were under 10p before the pandemic, and hit £3 for a few minutes based on the statements from company, and are now back to 50p. Meanwhile loads have been spiked as many were buying all the way up. I'm afraid the only thing that can get us out if this mess is BC or the AIHL, or else we'll be dropping further.
*Jam tomorrow is the whole point of investing! In simple terms you buy when the price is low before the jam has been delivered, when you know the price will multiply.*
Look at the 2 year price chart. I think the period of turning cheap fruit into expensive jam has been and gone.
IMHO DYOR
would that be August or September ?????. I dont think i have been invested in a share that has so much potential as GDR , but as with most aim shares that is what it is all about , potential .
Is it frustrating and annoying , YES. Have their been mistakes made ,imo another yes but i would be amazed if we dont get the FDA approval based on the fact that we have had approvals from a number of other bodies and then we can start getting sales numbers in as PCR and POC tests are going to be needed for a long while yet .
I feel we will get to £3 plus once we have approvals and sales figures but it may be over aperiod of time but the not knowing what is going on due to no update from the company means it is still a wait and see whether we like it all .
2823 may could be our month
Jam tomorrow is the whole point of investing! In simple terms you buy when the price is low before the jam has been delivered, when you know the price will multiply. If it was jam yesterday you will have been too late, jam today and you’ll be spiked :)
Check out on government.uk contracts
7,000,000 bid
Handling a logistics for covid testing
Warehouse storage
Start January 2022
End December 2022
Gla
Amazing isn't it Guy, those that kept calling those of us with balanced views derampers, whilst suggesting GDR was going to moon have changed their views in the blink of an eye. Perhaps reality is sinking in that without news, it's just people blowing smoke up each other's backside
Will swerves start unfiltering everyone now he’s turned deramper haha
Swerves are you the male version of Sally lol? You've gone from ramping to the moon, to now being realistic or "deramping" lol
Swerves that was almost certainly the NOMAD, not him.